Related Experiment Videos
Factor X inhibitors.
Kiat Tsong Tan1, Andrew Makin, Gregory Y H Lip
1Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK. g.y.h.lip@bham.ac.uk
Expert Opinion on Investigational Drugs
|May 2, 2003
Summary
Factor X is crucial for blood clotting and may link coagulation and inflammation. Inhibitors targeting Factor X are promising antithrombotic drugs for various conditions.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Factor X is a key enzyme in the coagulation cascade, integrating intrinsic and extrinsic pathways.
- Factor X may also mediate interactions between coagulation and inflammatory processes.
- Understanding Factor X's role is vital for developing novel antithrombotic therapies.
Purpose of the Study:
- To highlight Factor X as a potential therapeutic target for antithrombotic drug development.
- To review the current status and future prospects of Factor X inhibitors.
Main Methods:
- Literature review of Factor X's role in coagulation and inflammation.
- Analysis of existing and developing Factor X inhibitor therapies.
Main Results:
- Fondaparinux, a Factor X inhibitor, is approved for preventing deep vein thrombosis.
- Factor X inhibitors are under investigation for acute coronary syndromes, pulmonary embolism, and deep vein thrombosis.
- Oral Factor X inhibitors are being developed for stroke and thromboembolism prevention.
Conclusions:
- Factor X is a validated and attractive target for antithrombotic drug development.
- Existing and emerging Factor X inhibitors show significant therapeutic potential across a range of thromboembolic disorders.